Clinical-stage oncology biotech company Immunome announced on May 27 that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 9, 2026. The company presentation is set for 10:40 a.m. on that day. Investors can access the live webcast via the investor relations section of the company's website, with a replay available approximately 30 days after the event.
**Key Pipeline Asset: Varegacestat NDA Submitted** Immunome's most closely watched core asset is varegacestat, an investigational gamma-secretase inhibitor for the treatment of adult desmoid tumors. The company submitted a New Drug Application to the U.S. Food and Drug Administration in April 2026. This submission is based on positive results from the global Phase III RINGSIDE trial, which met its primary endpoint of improved progression-free survival, demonstrating an 84% reduction in the risk of disease progression or death compared to placebo. All key secondary endpoints also achieved statistical significance. The company also plans to submit a Marketing Authorization Application to the European Medicines Agency by the end of 2026. Detailed Phase III data has been selected for an oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting.
**ADC Pipeline Progressing Steadily: IM-1021 Clinical Data Expected in 2026** In its antibody-drug conjugate pipeline, the Phase I clinical trial for IM-1021, an ROR1-targeting ADC candidate, is ongoing. Objective responses have been observed at multiple dose levels in patients with B-cell lymphoma, and the company anticipates reporting initial lymphoma data in 2026. Another asset, the FAP-targeting radiopharmaceutical therapy IM-3050, has received IND clearance, with its Phase I trial initiating in March 2026. IM-1617, a potential first-in-class ADC targeting an undisclosed solid tumor target, has also received IND clearance, with plans to initiate a Phase I trial in the second quarter of 2026. Furthermore, the company expects to submit IND applications for IM-1340 and IM-1335 in mid-2026 and late-2026, respectively. These ADCs also utilize the HC74 payload and target undisclosed solid tumor targets.
**Financial Position: Strong Cash Reserves, Q1 Results Beat Expectations** As of March 31, 2026, Immunome held approximately $582.7 million in cash and cash equivalents. The company stated that its existing funds are sufficient to support operations into 2028. A public offering completed in December 2025 provided total gross proceeds of approximately $460.5 million. For the first quarter of 2026, research and development expenses were $46.4 million, while general and administrative expenses were $13.0 million. The reported net loss per share for the quarter was $0.48, surpassing the market expectation of a $0.60 loss per share. Immunome is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies. Its leadership team possesses extensive experience in the design, development, and commercialization of cutting-edge therapies, including ADCs. The current Wall Street analyst consensus rating for the stock is "Moderate Buy," with an average price target of approximately $32.82.
Comments